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PMH7
TRENDS AND PATTERNS IN THE DIAGNOSIS AND PRESCRIBING OF 
PSYCHOTROPIC MEDICATIONS IN CHILDREN AND ADOLESCENTS 
WITH ADHD.
Kelwalkar A1, Nayak R2
1St John’s University, Jamaica, NY, USA, 2St.John’s University, Jamaica, NY, USA
OBJECTIVES: Our study seeks to assess national variations in physician diagnosis of 
Attention Deﬁcit Hyperactivity Disorder (ADHD) and test a hypothesis that family 
practitioners are more likely to diagnose and prescribe medications for ADHD than 
specialists. Further, the study seeks to examine trends and patterns in the use of stimu-
lant medications in children and adolescents with ADHD. METHODS: We used data 
from National Ambulatory Medicare Care Survey (NAMCS), an on-going annual 
survey of a representative sample of US ofﬁce-based physician practices. The frequency 
and rate of ADHD-related visits were analyzed using a weighted sample of youths 
aged 18 years and younger and trends were tracked for diagnostic prevalence and 
psychotropic medication use for the years 2003–2006. Utilization of psychotropic 
medications was focused on stimulant drug use and second line ADHD medications. 
RESULTS: A total of 5,319,764 visits having ADHD as primary diagnosis were identi-
ﬁed in 2006, representing an increase of about 11% from 2003. The primary diagnosis 
of ADHD was made increasingly by non specialist physicians (pediatricians, family 
practitioners, internists and others; from 43.3% in 2003 to 64.9 % in 2006) compared 
to specialists (child and general psychiatrists and neurologists) during the period 
covered. As pediatrician diagnosis of ADHD rose from to 32.5% in 2003 to 50% in 
2006, diagnosis by child psychiatrists declined signiﬁcantly from 37.3% to 18.9% (P 
< 0.05) during the same period. The prescribing of long-acting stimulants increased 
from 42.8 % in 2003 to 47.1 % in 2006, and an opposite trend was observed for the 
short-acting agents during the same period (decreased by 8.5 %). CONCLUSIONS: 
Nonspecialist physicians are more likely to diagnose ADHD and prescribe psychotro-
pic medications than specialists, further underscoring the controversy surrounding 
ADHD treatment. Dramatic changes in the patterns of psychotropic medication use 
in outpatient medical practice may be a cause for concern.
PMH8
IMPROVED TREATMENT OUTCOMES FOLLOWING A SWITCH FROM 
RISPERIDONE TO OLANZAPINE IN A 1-YEAR NATURALISTIC STUDY 
OF SCHIZOPHRENIA PATIENTS IN JAPAN
Ye W1, Fujikoshi S1, Nakahara N1, Takahashi M1, Ascher-Svanum H2
1Eli Lilly Japan K.K, Kobe, Japan, 2Eli Lilly & Co., Indianapolis, IN, USA
OBJECTIVES: This study assessed the clinical and functional outcomes following a 
switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia 
patients in Japan. METHODS: We used data from a large 1-year prospective, multi-
center, observational non-interventional study of individuals who were initiated on 
olanzapine for the treatment of schizophrenia in Japan. Current analysis focused on 
patients who were switched at study entry from risperidone to olanzapine (n = 258). 
Changes from baseline to endpoint on clinical and functional measures were assessed 
with validated measures. Repeated measures analysis was employed for longitudinal 
measures. RESULTS: At study entry, 45% were inpatients and 55% outpatient. 
Participants were in their early 40s’ with mean illness duration of 14 years. About 
half were male. Most were switched from risperidone to olanzapine due to poor 
medication efﬁcacy (67.8%) and fewer were switched due to medication intolerability 
(29.1%). Most patients (67.8%) completed the 1-year study. During the follow up 
period, patients experienced clinically meaningful and statistically signiﬁcant (p < 0.05) 
improvements in overall symptom levels, on positive, negative, depressive and cogni-
tive symptoms, on quality of life and on paid work rates. Most patients (59.2%) 
demonstrated treatment response to olanzapine and 43.4% experienced symptom 
remission. Mean weight gain was 2.19 kg, with one- third of patients experiencing 
clinically meaningful weight gain (at least 7% of baseline weight). Most patients 
(76.0%) maintained their initial BMI category. CONCLUSIONS: In this 1-year natu-
ralistic study of patients with schizophrenia in Japan, inpatients and outpatients who 
were switched from risperidone to olanzapine experienced clinically meaningful and 
statistically signiﬁcant improvements in their clinical and functional outcomes, which 
were accompanied by a clinically meaningful weight gain for one-third of the patients. 
Current ﬁndings highlight the favorable beneﬁt to risk proﬁle of switching to olan-
zapine therapy following treatment failure on risperidone among schizophrenia 
patients in Japan.
PMH9
PATIENTS’ EARLY PERCEPTIONS OF MEDICATIONS’ BENEFITS 
PREDICT SUBSEQUENT RESPONSE IN THE TREATMENT OF 
SCHIZOPHRENIA
Nyhuis A1, Ascher-Svanum H1, Faries D1, Stauffer VL2, Kollack-Walker S2, Kinon BJ1, 
Weiden PJ3
1Eli Lilly and Company, Indianapolis, IN, USA, 2Lilly USA, LLC, Indianapolis, IN, USA, 
3University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: To assess whether a brief and simple assessment of patients’ early 
perceptions of medications’ beneﬁts can predict subsequent response or non-response 
to continued treatment with the same antipsychotic medication. METHODS: This 
post-hoc analysis used data from a cost-effectiveness study of antipsychotics in the 
treatment of schizophrenia (HGGD) in which the Rating of Medication Inﬂuences 
scale (ROMI) was assessed following 2 weeks of treatment. Patients rated ROMI items 
on a scale from 1 (no agreement) to 3 (strong agreement). Patients’ scores on the 
ROMI’s “Perceived Medication Beneﬁts,” a 4-item subscale identiﬁed in prior 
research, were used to predict subsequent response to continued treatment with the 
medication at Week 8. Response was deﬁned as at least 20% reduction on the Positive 
and Negative Syndrome Scale (PANSS) total score from baseline to Week 8. Logistic 
regression was used to assess whether the ROMI “Perceived Medication Beneﬁts” 
score was a strong predictor of subsequent response and identify the best cut-off score 
for the prediction model. Analysis was conducted on 439 patients who had PANSS 
and ROMI data at the 2-week and 8-week time points. RESULTS: A score of 2.75 
or higher on the Perceived Medication Beneﬁts subscale at Week 2 predicted subse-
quent response (per PANSS) at Week 8 with high speciﬁcity (72%) and negative 
predictive value (70%), moderate sensitivity (44%) and positive predictive value 
(47%) and with a 38% misclassiﬁcation rate. CONCLUSIONS: A brief assessment 
of patients’ early perceptions of medications’ beneﬁts (at Week 2) appears to be a 
good predictor of subsequent response/non-response to continued treatment with the 
same medication. Predictive values appear comparable to those reported in prior 
studies in which early response was assessed with a clinician-rated symptom scale, 
which requires special training and repeated assessments. Further research is needed 
to replicate the current ﬁndings.
PMH10
LONG-TERM OUTCOMES AFTER SWITCHING FROM TYPICAL 
ANTIPSYCHOTICS TO OLANZAPINE AMONG SCHIZOPHRENIA 
PATIENTS IN JAPAN
Ye W1, Fujikoshi S1, Nakahara N1, Takahashi M1, Ascher-Svanum H2
1Eli Lilly Japan K.K, Kobe, Japan, 2Eli Lilly & Co., Indianapolis, IN, USA
OBJECTIVES: To assess the long-term clinical, functional and safety-related outcomes 
following a switch from typical antipsychotics to olanzapine in the treatment of 
schizophrenia patients in Japan. METHODS: Using data from a large 1-year prospec-
tive, multi-center, observational non-interventional study of olanzapine for the treat-
ment of schizophrenia in Japan, patients who were switched from any oral typical 
antipsychotic to olanzapine were identiﬁed. Changes from baseline to endpoint in 
clinical and functional measures and in body weight were evaluated. Mixed model 
with repeated measures, controlled for baseline demographics, were applied. 
RESULTS: Of 262 patients who switched from typical antipsychotics to olanzapine, 
41% were outpatients and 59% inpatient. Most of these patients (71.0%) were 
switched due to poor medication efﬁcacy and 25.6% due to medication intolerability. 
Participants, on average, were chronically ill, in their late 40’s, with a 20-year history 
of schizophrenia. About half (51.9%) were male. Most patients (71.4%) completed 
the 1-year study. Clinically meaningful and statistically signiﬁcant (p < 0.01) improve-
ments from baseline to the ﬁnal study visit were observed in patients’ illness severity 
and quality of life, with improvements in overall symptom severity level and in posi-
tive, negative, depressive and cognitive symptoms. Most patients (58.3%) demon-
strated a treatment response to olanzapine and 47.4% achieved symptom remission. 
Mean weight gain from baseline to endpoint was 2.31 ± 4.72 kg, with 30.4% of 
patients experiencing clinically meaningful weight gain (at least 7% of baseline 
weight). Most (75.6%) patients maintained their initial BMI category at baseline. 
CONCLUSIONS: During the long-term naturalistic treatment of schizophrenia 
patients in Japan, the switching from typical antipsychotics to olanzapine appears to 
result in signiﬁcant improvements in patients’ clinical and functional outcomes, this 
is associated with clinically meaningful weight gain in one-third of patients. Findings 
highlight the potential beneﬁts and risks associated with switching to olanzapine fol-
lowing failure on typical antipsychotics.
PMH11
DISCRETE EVENT SIMULATION MODEL IN MAJOR DEPRESSIVE 
DISORDER: LIFE-TIME HEALTH OUTCOMES OF ADJUNCTIVE ATYPICAL 
ANTIPSYCHOTICS
Treur M1, Pitchot W2, Postema R1, Loze JY3, Heeg B1, Drost P4
1Pharmerit Europe, Rotterdam, -, The Netherlands, 2CHU Liege, Liege, Belgium, 3Otsuka 
Pharmaceutical Co., Ltd., Rueil-Malmaison, -, France, 4Bristol-Myers Squibb, Braine-l’Alleud, 
Belgium
OBJECTIVES: Adjunctive treatments with atypical antipsychotics have demonstrated 
efﬁcacy in major depressive disorder (MDD) patients that respond insufﬁciently to 
conventional antidepressants. As most trial designs have limited duration, simulation 
allows for extrapolation, to inform on optimal treatment sequences over a longer 
period. We estimated the life-time health outcomes for augmentation therapies with 
atypical antipsychotics in MDD patients who fail to respond to conventional antide-
pressants. METHODS: A discrete event simulation model was built simulating MDD 
patients between major depressive episodes (MDEs) and remission periods over life-
time based on published data. During MDEs, patients were treated with adjunctive 
aripiprazole, quetiapine or olanzapine. Patients who did not respond at 6 weeks were 
switched to subsequent treatment lines. Comparative effectiveness between treatments 
was imputed using an indirect comparison combining 6-week published studies. 
Health related quality of life (QoL) data were obtained from published studies. 
Uncertainty of results was assessed by probabilistic sensitivity analyses (PSA). 
RESULTS: Over life-time, compared to adjunctive quetiapine and olanzapine, patients 
starting on adjunctive aripiprazole spent less time in MDEs compared to quetiapine 
(0.11 years) and olanzapine (0.17 years) and had an improvement of 0.06 and 0.04 
quality adjusted life years respectively. PSA estimated an 88% and 80% probability 
that aripiprazole improved QoL compared to quetiapine and olanzapine respectively. 
CONCLUSIONS: This novel DES model is well suited to account for the highly 
heterogeneous patient population, the deteriorating disease course and the use of 
different sequential treatment alternatives that is speciﬁc to MDD. The results indicate 
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that adjunctive treatment with aripiprazole provides health beneﬁts compared to 
quetiapine and olanzapine in patients with MDD that fail to respond to conventional 
antidepressants. With country speciﬁc cost-data, this model is also suited to assess the 
cost-effectiveness of different adjunctive strategies in MDD in different countries.
PMH12
THE COMPARATIVE EFFICACY OF INJECTABLE AND ORAL ATYPICAL 
ANTIPSYCHOTICS IN REDUCING RELAPSES IN ADULT 
SCHIZOPHRENIA PATIENTS: A SYSTEMATIC REVIEW AND MIXED 
TREATMENT COMPARISON ANALYSIS
Blume S1, Naci H2, Green J3, Fleischmann J4, Gaudig M4
1United BioSource Corporation, Bethesda, MD, USA, 2United BioSource Corporation, 
London, MD, UK, 3United BioSource Corporation, Lexington, MA, USA, 4Janssen-Cilag 
Germany, Neuss, Germany
OBJECTIVES: To compare injectable and oral atypical antipsychotics in reducing 
relapses in adult schizophrenia patients. METHODS: A systematic review of literature 
was conducted in MEDLINE and EMBASE (January 1995-August 2009) to identify 
randomized controlled trials and comparative open-label studies of atypical antipsy-
chotics performed on adult schizophrenia outpatients. Proceedings of the American 
Psychiatric Association Conference from 2006 to 2009 and bibliographies of identiﬁed 
studies and relevant reviews were also searched. Included studies had to have a clear 
deﬁnition of relapse (e.g. hospitalization or return to symptomatic condition), and a 
minimum follow-up period of 6 months. Comparators included atypical antipsychot-
ics, typical antipsychotics, or placebo. Data extraction was validated by a second 
reviewer. A Bayesian mixed treatment comparison (MTC), enabling indirect compari-
sons of interventions while respecting randomization, was performed on the rate of 
relapse assuming random study effects. RESULTS: Ten articles were identiﬁed and 
included in the systematic review and MTC. The odds ratio (OR) [95% credible 
interval (CI)] of relapse relative to placebo ranged from 0.13 [0.04, 0.47] (oral 
risperidone) to 0.20 [0.03, 1.19] (aripiprazole) among oral atypical agents, and 0.29 
[0.07, 1.12] for typical agent haloperidol. The OR [95% CI] of relapse of injectible 
risperidone relative to oral formulations of atypicals ranged from 0.28 [0.05, 1.24] 
(aripiprazole) to 0.41 [0.12, 1.01] (olanzapine). Injectable risperidone had lower odds 
of relapse than oral risperidone, olanzapine, quetiapine, aripiprazole, combination 
therapy, haloperidol, and placebo with probabilities > 95% and quetiapine XR, clo-
zapine, and ziprasidone with probabilities of 85%, 90%, and 93%, respectively. 
Findings were robust to varying trial durations and responder deﬁnitions. CONCLU-
SIONS: Oral formulations of various atypical antipsychotics, as well as typical halo-
peridol, offer similar beneﬁts over placebo in reducing relapse rates. Statistical and 
clinically important differences in relapse rates exist between oral and injectable for-
mulations of atypicals in favor of injectable risperidone.
PMH13
CHARACTERISTICS AND COST OUTCOMES OF INSURED PATIENTS 
TREATED WITH EXTENDED-RELEASE NALTREXONE (XR-NTX) OR 
ORAL ALCOHOL DEPENDENCE MEDICATIONS
Mark TL1, Gastfriend DR2, Kranzler HR3, Chalk M4, Montejano L1
1Thomson Reuters, Washington, DC, USA, 2Alkermes, Inc, Cambridge, MA, USA, 3University 
of Connecticut School of Medicine, Farmington, CT, USA, 4Treatment Research Institute, 
Philadelphia, PA, USA
OBJECTIVES: There are four FDA-approved alcoholism medications: disulﬁram, 
naltrexone, acamprosate, and extended-release naltrexone (XR-NTX). This study used 
observational data to evaluate the utilization and cost outcomes of insured patients 
treated with alcohol medications or no medication. METHODS: Data were from 
Thomson Reuter’s MarketScan Commercial insurance claims database which contains 
information from millions of enrollees annually. Outcomes were measured six months 
after index and included medication possession ratio (MPR), detoxiﬁcation admissions 
and days, alcohol-related admissions and days, ED visits, psychiatric and substance 
abuse outpatient visits and charges for detoxiﬁcation and alcohol-related inpatient 
stays. Two sets of analyses were conducted: 1) Persons with an alcohol use disorder 
and no use of any alcohol medication (n = 4,047) were compared to persons with an 
alcohol use disorder and use of any of the four medications (n = 4,730). The samples 
were propensity-score matched on demographics, clinical characteristics and prior use 
of alcohol and psychiatric services, and 2) The four medications were compared 
(XR-NTX n = 275; naltrexone n = 2064 acamprosate n = 5068; disulﬁram n = 2076) 
using inverse probability weighting. RESULTS: The probability of any detoxiﬁcation 
admission, alcohol-related admission, and ED visit and a substance abuse or psychi-
atric visit was signiﬁcantly higher among no medication users than medications users. 
XR-naltrexone users had a signiﬁcantly higher MPR than acamprosate users. Patients 
using any medication had fewer detoxiﬁcation days and alcoholism-related inpatient 
days. Among medication users, XR-NTX was associated with signiﬁcantly lower 
detoxiﬁcation costs (per 1000 patients over 6 months) versus oral naltrexone, disul-
ﬁram and acamprosate (Detox: $0.60-million vs. $1.48-million, $1.08-million, $1.40-
million; respectively; P < 0.01 for XR-NTX vs. naltrexone and acamprosate). 
CONCLUSIONS: Individuals receiving alcoholism medications had signiﬁcantly and 
substantially lower detoxiﬁcation and hospitalization utilization rates than similar 
patients who received no medication. Of the approved medications, XR-TX had lower 
costs for detoxiﬁcation and alcoholism hospitalization days.
PMH14
ALL-CAUSE TREATMENT DISCONTINUATION FOR OLANZAPINE 
COMPARED TO OTHER ANTIPSYCHOTICS IN THE TREATMENT OF 
SCHIZOPHRENIA: A META-ANALYSIS
Soares-Weiser K1, Bechard-Evans L1, Lawson AH2, Davis J3, Ascher-Svanum H2
1Enhance Reviews, Ltd., London, England, UK, 2Eli Lilly and Company, Indianapolis, IN, USA, 
3University of Illinois, Chicago, IL, USA
OBJECTIVES: Treatment discontinuation has been increasingly used as a quantiﬁable 
tool for measuring the overall effectiveness of antipsychotic medications, including 
efﬁcacy, safety, and tolerability of a drug. While results have been inconsistent, several 
studies have found that olanzapine and other second-generation antipsychotics (SGA) 
are more effective in the treatment of schizophrenia compared to ﬁrst-generation 
antipsychotics (FGA). This meta-analysis compared time to and rate of treatment 
discontinuation of antipsychotics in schizophrenia. METHODS: Electronic search 
strategies identiﬁed all relevant papers on the topic published up to April 2009. 
Randomized controlled trials (RCTs) and observational studies that compared olan-
zapine with SGAs and/or FGAs for patients with schizophrenia were included in the 
meta-analyses. Hazard ratios (HR), Relative Risks (RR) and their associated 95% 
conﬁdence intervals (CIs) were extracted. RESULTS: There were 60 RCTs (N = 
33,360) and 27 observational studies (N = 202,591) included. The meta-analysis of 
time to discontinuation revealed that olanzapine was signiﬁcantly better as compared 
to aripiprazole, quetiapine, risperidone, ziprasidone, and perphenazine within ran-
domized trials and better than amisulpride, risperidone, haloperidol, and perphenazine 
within observational studies. Discontinuation rates in the RCTs were signiﬁcantly 
lower for olanzapine compared to all antipsychotics except for clozapine. In the 
observational studies, olanzapine was more effective than amisulpride and haloperi-
dol, and less effective than clozapine. Subgroup analysis indicated that industry spon-
sorship (Lilly vs. other sources) and olanzapine dosages did not affect the results, 
except for observational studies published by companies other than Lilly which found 
olanzapine to be more favorable compared to FGAs). CONCLUSIONS: In both 
randomized trials and observational studies, time to and rates of discontinuation, 
which are overall indices of effectiveness, olanzapine was better than most SGAs and 
FGAs, except for clozapine.
PMH15
PREDICTORS OF FAVORABLE LONG-TERM OUTCOME IN THE 
TREATMENT OF SCHIZOPHRENIA
Cuyun Carter G, Milton D, Faries D, Ascher-Svanum H
Eli Lilly and Company, Indianapolis, IN, USA
OBJECTIVES: This study aimed to identify schizophrenia patients who experience 
favorable outcomes over a 3-year period and determine baseline predictors of favor-
able long-term outcomes. METHODS: We used data of a 3-year prospective, obser-
vational study of individuals treated for schizophrenia in the United States (US-SCAP; 
N = 2327). A hierarchical cluster analysis was performed to group patients, using 
baseline clinical, functional, and resource utilization measures. Clinical status was 
based on symptom severity. Functional level reﬂected patient-reported productivity 
and occupational role functioning. Resource utilization of psychiatric hospitalization 
and emergency services was systematically abstracted from medical records. A patient 
was classiﬁed as having a favorable long term outcome if their outcome values had 
the closest distance to the deﬁned “best baseline cluster” at each point over the 3-year 
follow-up; stepwise logistic regression was used to determine baseline predictors. 
RESULTS: Of 1604 patients with sufﬁcient data to assess 3-year outcomes, only 191 
(12%) experienced favorable outcomes. Overall, 5 distinct outcome clusters were 
identiﬁed, ranging from best to worst. The baseline predictors of the most favorable 
outcomes sustained over the 3-year period included better quality of life, more daily 
activities, patient-reported clearer thinking, less severe positive symptoms, lower AIMS 
score, higher level of global functioning, being employed, not having health insurance, 
being female, and not having help with shopping, leisure, or social activities. CON-
CLUSIONS: This study identiﬁed 5 distinct clusters of patients with schizophrenia 
based on their baseline clinical, functional, and resource utilization factors. Current 
ﬁndings suggest that clinicians could make early projections of long-term outcome, 
thus enabling early tailored therapeutic interventions that could enhance patient’s 
likelihood of achieving more favorable long-term outcomes.
PMH16
THE COMPARATIVE EFFICACY AND SAFETY OF ADJUNCTIVE 
ANTIPSYCHOTICS IN MAJOR DEPRESSIVE DISORDER PATIENTS THAT 
FAILED TO RESPOND TO CONVENTIONAL ANTIDEPRESSANTS
Treur M1, Postema R1, Loze JY2, Howing N1, Drost P3, Pitchot W4
1Pharmerit Europe, Rotterdam, -, The Netherlands, 2Otsuka Pharmaceutical Co., Ltd., 
Rueil-Malmaison, -, France, 3Bristol-Myers Squibb, Braine-l’Alleud, Belgium, 4CHU Liege, Liege, 
Belgium
OBJECTIVES: Augmentation with atypical antipsychotics are effective in treating 
patients suffering from major depressive disorder (MDD) and that respond insufﬁ-
ciently to conventional antidepressants. Direct head-to-head trials comparing these 
agents are lacking. An indirect comparison was conducted to assess the comparative 
efﬁcacy and safety of augmentation with atypical antipsychotics in MDD. METHODS: 
A systematic literature search was conducted of Medline/PubMed (1966-September 
2009). Eligible trials enrolled patients diagnosed with unipolar major depressive dis-
order with resistance to at least one prior antidepressant. Trials had to be double-blind 
placebo controlled assessing the efﬁcacy and/or safety of augmentation therapy with 
aripiprazole, quetiapine, or olanzapine during an acute depressive episode. Response 
